179 related articles for article (PubMed ID: 18351427)
1. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.
Sunyecz JA; Mucha L; Baser O; Barr CE; Amonkar MM
Osteoporos Int; 2008 Oct; 19(10):1421-9. PubMed ID: 18351427
[TBL] [Abstract][Full Text] [Related]
2. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
3. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG
Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689
[TBL] [Abstract][Full Text] [Related]
4. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
5. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
[TBL] [Abstract][Full Text] [Related]
6. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
7. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.
Cramer JA; Lynch NO; Gaudin AF; Walker M; Cowell W
Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124
[TBL] [Abstract][Full Text] [Related]
8. Cost and consequences of noncompliance to oral bisphosphonate treatment.
Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
11. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical and economic impact of nonadherence with osteoporosis medications.
Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
[TBL] [Abstract][Full Text] [Related]
14. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
Rabenda V; Mertens R; Fabri V; Vanoverloop J; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
[TBL] [Abstract][Full Text] [Related]
15. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J;
Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671
[TBL] [Abstract][Full Text] [Related]
16. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
[TBL] [Abstract][Full Text] [Related]
17. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
Cotté FE; Mercier F; De Pouvourville G
Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
[TBL] [Abstract][Full Text] [Related]
18. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
Cramer JA; Gold DT; Silverman SL; Lewiecki EM
Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
[TBL] [Abstract][Full Text] [Related]
20. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
Ganda K; Schaffer A; Pearson S; Seibel MJ
Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
